Is the Disease Burden from COPD in Norway Falling off? A Study of Time Trends in Three Different Data Sources

BACKGROUND: Less smoking should lead to fewer COPD cases. We aimed at estimating time trends in the prevalence and burden of COPD in Norway from 2001 to 2017. METHODS: We used pre-bronchodilator spirometry and other health data from persons aged 40–84 years in three surveys of the Tromsø Study, 2001...

Full description

Bibliographic Details
Published in:International Journal of Chronic Obstructive Pulmonary Disease
Main Authors: Melbye, Hasse, Helgeland, Jon, Karlstad, Øystein, Ariansen, Inger, Langhammer, Arnulf, Wisløff, Torbjørn, Nafstad, Per, Nystad, Wenche
Format: Text
Language:English
Published: Dove 2020
Subjects:
Online Access:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024866/
https://doi.org/10.2147/COPD.S235106
id ftpubmed:oai:pubmedcentral.nih.gov:7024866
record_format openpolar
spelling ftpubmed:oai:pubmedcentral.nih.gov:7024866 2023-05-15T18:34:31+02:00 Is the Disease Burden from COPD in Norway Falling off? A Study of Time Trends in Three Different Data Sources Melbye, Hasse Helgeland, Jon Karlstad, Øystein Ariansen, Inger Langhammer, Arnulf Wisløff, Torbjørn Nafstad, Per Nystad, Wenche 2020-02-12 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024866/ https://doi.org/10.2147/COPD.S235106 en eng Dove http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024866/ http://dx.doi.org/10.2147/COPD.S235106 © 2020 Melbye et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). CC-BY-NC Original Research Text 2020 ftpubmed https://doi.org/10.2147/COPD.S235106 2020-03-01T01:25:41Z BACKGROUND: Less smoking should lead to fewer COPD cases. We aimed at estimating time trends in the prevalence and burden of COPD in Norway from 2001 to 2017. METHODS: We used pre-bronchodilator spirometry and other health data from persons aged 40–84 years in three surveys of the Tromsø Study, 2001–2002, 2007–2008 and 2015–2016. We applied spirometry lower limits of normal (LLN) according to Global Lung Initiative 2012. Age-standardized prevalence was determined. We defined COPD as FEV(1)/FVC<LLN in subjects reporting dyspnea or coughing, and moderate to severe COPD when FEV(1) <LLN was found in addition. We identified hospitalizations due to COPD exacerbations in the Norwegian Patient Registry 2010–2017, and retrieved the use of COPD medication from the Norwegian Prescription Database. Change in prevalence was analyzed by logistic regression. RESULTS: In the Tromsø Study, the age-standardized prevalence of daily smoking dropped from 29.9% to 14.1% among women and from 31.4% to 12.8% among men (P<0.0001). The age-standardized prevalence of COPD dropped from 7.6% to 5.6% among women (P=0.2) and from 7.3% to 5.6% among men (P=0.003) and of moderate to severe COPD from 5.2% to 2.7% among women (P=0.0003) and from 4.6% to 3.2% among men (P=0.0008). Among men, the yearly age-standardized prevalence of hospitalization due to COPD exacerbation decreased from 3.6 to 3.0 per 1000 inhabitants aged 40–84 years (P<0.0001). Correspondingly, dispensing oral corticosteroids or/and antibiotics for COPD exacerbations dropped from 6.6 to 5.8 per 1000 (P<0.0001), while dispensing maintenance treatment increased (P<0.0001). CONCLUSION: COPD morbidity decreased between 2001 and 2017, which might partly be due to less smoking. The drop in smoking prevalence gives promise of a further substantial decrease in the coming decades. Text Tromsø PubMed Central (PMC) Norway Tromsø International Journal of Chronic Obstructive Pulmonary Disease Volume 15 323 334
institution Open Polar
collection PubMed Central (PMC)
op_collection_id ftpubmed
language English
topic Original Research
spellingShingle Original Research
Melbye, Hasse
Helgeland, Jon
Karlstad, Øystein
Ariansen, Inger
Langhammer, Arnulf
Wisløff, Torbjørn
Nafstad, Per
Nystad, Wenche
Is the Disease Burden from COPD in Norway Falling off? A Study of Time Trends in Three Different Data Sources
topic_facet Original Research
description BACKGROUND: Less smoking should lead to fewer COPD cases. We aimed at estimating time trends in the prevalence and burden of COPD in Norway from 2001 to 2017. METHODS: We used pre-bronchodilator spirometry and other health data from persons aged 40–84 years in three surveys of the Tromsø Study, 2001–2002, 2007–2008 and 2015–2016. We applied spirometry lower limits of normal (LLN) according to Global Lung Initiative 2012. Age-standardized prevalence was determined. We defined COPD as FEV(1)/FVC<LLN in subjects reporting dyspnea or coughing, and moderate to severe COPD when FEV(1) <LLN was found in addition. We identified hospitalizations due to COPD exacerbations in the Norwegian Patient Registry 2010–2017, and retrieved the use of COPD medication from the Norwegian Prescription Database. Change in prevalence was analyzed by logistic regression. RESULTS: In the Tromsø Study, the age-standardized prevalence of daily smoking dropped from 29.9% to 14.1% among women and from 31.4% to 12.8% among men (P<0.0001). The age-standardized prevalence of COPD dropped from 7.6% to 5.6% among women (P=0.2) and from 7.3% to 5.6% among men (P=0.003) and of moderate to severe COPD from 5.2% to 2.7% among women (P=0.0003) and from 4.6% to 3.2% among men (P=0.0008). Among men, the yearly age-standardized prevalence of hospitalization due to COPD exacerbation decreased from 3.6 to 3.0 per 1000 inhabitants aged 40–84 years (P<0.0001). Correspondingly, dispensing oral corticosteroids or/and antibiotics for COPD exacerbations dropped from 6.6 to 5.8 per 1000 (P<0.0001), while dispensing maintenance treatment increased (P<0.0001). CONCLUSION: COPD morbidity decreased between 2001 and 2017, which might partly be due to less smoking. The drop in smoking prevalence gives promise of a further substantial decrease in the coming decades.
format Text
author Melbye, Hasse
Helgeland, Jon
Karlstad, Øystein
Ariansen, Inger
Langhammer, Arnulf
Wisløff, Torbjørn
Nafstad, Per
Nystad, Wenche
author_facet Melbye, Hasse
Helgeland, Jon
Karlstad, Øystein
Ariansen, Inger
Langhammer, Arnulf
Wisløff, Torbjørn
Nafstad, Per
Nystad, Wenche
author_sort Melbye, Hasse
title Is the Disease Burden from COPD in Norway Falling off? A Study of Time Trends in Three Different Data Sources
title_short Is the Disease Burden from COPD in Norway Falling off? A Study of Time Trends in Three Different Data Sources
title_full Is the Disease Burden from COPD in Norway Falling off? A Study of Time Trends in Three Different Data Sources
title_fullStr Is the Disease Burden from COPD in Norway Falling off? A Study of Time Trends in Three Different Data Sources
title_full_unstemmed Is the Disease Burden from COPD in Norway Falling off? A Study of Time Trends in Three Different Data Sources
title_sort is the disease burden from copd in norway falling off? a study of time trends in three different data sources
publisher Dove
publishDate 2020
url http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024866/
https://doi.org/10.2147/COPD.S235106
geographic Norway
Tromsø
geographic_facet Norway
Tromsø
genre Tromsø
genre_facet Tromsø
op_relation http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024866/
http://dx.doi.org/10.2147/COPD.S235106
op_rights © 2020 Melbye et al.
http://creativecommons.org/licenses/by-nc/3.0/
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
op_rightsnorm CC-BY-NC
op_doi https://doi.org/10.2147/COPD.S235106
container_title International Journal of Chronic Obstructive Pulmonary Disease
container_volume Volume 15
container_start_page 323
op_container_end_page 334
_version_ 1766219296292208640